These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22134426)

  • 1. Xigris is withdrawn from the market. A 10 year odyssey.
    Suter PM
    Minerva Anestesiol; 2011 Dec; 77(12):1128-9. PubMed ID: 22134426
    [No Abstract]   [Full Text] [Related]  

  • 2. The last Xigris® survivor.
    Barie PS
    Surg Infect (Larchmt); 2011 Dec; 12(6):423-5. PubMed ID: 22185189
    [No Abstract]   [Full Text] [Related]  

  • 3. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 4. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.
    Barie PS
    Surg Infect (Larchmt); 2007 Oct; 8(5):491-4. PubMed ID: 17999581
    [No Abstract]   [Full Text] [Related]  

  • 5. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 7. Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris.
    Green RS; Djogovic D; Howes D
    CJEM; 2012 Sep; 14(5):265-9. PubMed ID: 22967692
    [No Abstract]   [Full Text] [Related]  

  • 8. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
    Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C
    Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.
    de Pont AC; Bakx R; Boermeester MA; Schultz MJ
    Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262
    [No Abstract]   [Full Text] [Related]  

  • 10. Drotrecogin alfa on trial.
    Tillotson GS
    Lancet Infect Dis; 2009 Jan; 9(1):2-3. PubMed ID: 19095188
    [No Abstract]   [Full Text] [Related]  

  • 11. [PROWESS--milestone in lowering sepsis mortality].
    Reinhart K
    Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
    [No Abstract]   [Full Text] [Related]  

  • 12. Editors' comments on a new trial of activated protein C for persistent septic shock.
    Mancebo J; Antonelli M
    Intensive Care Med; 2008 Nov; 34(11):1948-9. PubMed ID: 18839138
    [No Abstract]   [Full Text] [Related]  

  • 13. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 14. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 15. Kigris. FDA approves first biologic for sepsis.
    Nursing; 2002 Feb; 32(2):18. PubMed ID: 11924158
    [No Abstract]   [Full Text] [Related]  

  • 16. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside.
    Maki DG
    Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617
    [No Abstract]   [Full Text] [Related]  

  • 17. [On activated protein C in septic shock].
    Offenstadt G
    Presse Med; 2006 Jun; 35(6 Pt 1):989; author reply 989. PubMed ID: 16783262
    [No Abstract]   [Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 19. Drotrecogin alfa: excess mortality in the least severely ill patients.
    Prescrire Int; 2005 Aug; 14(78):145. PubMed ID: 16108104
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.